top of page

Project description

The purpose of the project

The aim of the AMINOPROFEN project is new generation pharmaceuticals from natural raw materials (amino acids) for use as non-steroidal anti-inflammatory drugs. These drugs will be a modification of known drugs from this group. The expected competitive advantage over existing drugs with analgesic, antipyretic and anti-inflammatory properties is improved solubility in body fluids and increased permeability through biological membranes (in particular through the skin), and thus increased bioavailability and favorable release profile of the therapeutic agent, so it will be better tolerated by the patient. In addition, changing the acid nature of the starting active substance will reduce the occurrence of negative side effects of these compounds, mainly their negative effect on the gastrointestinal tract, including weakening of the ulcerative effect.
The measurable goal of the project is to develop two products with improved properties in solid and semi-solid form. The preparation of drugs containing alkyl esters of NSAIDs in liquid form will additionally eliminate the adverse phenomenon of polymorphism. In addition to the use of the active substance modified with natural raw materials, the project goal will be achieved by appropriate selection of glue and/or membrane (in the case of a dermal patch) and gel base (in the case of a gel). Modification of the active substance structure and appropriate selection of excipients will allow the creation of safer drugs, in particular, due to the possibility of reducing the therapeutic dose of the drug and reducing adverse effects. In addition, the prices of raw materials used for modification will not affect the increase in the cost of production of the finished drug form due to the possibility of reducing excipients, among other absorption promoters. Thanks to the mentioned advantages, the final product has a serious potential to become a best-seller in the pharmaceutical industry - the OTC drug market.



"Technology development to receive new drug modifications with increased skin permeability"

The project is financed by the National Center for Research and Development as part of the LIDER XI competition, project number LIDER/53/0225/L-11/19/NCBR/2020


Project implementation period

January 2, 2021 - January 2, 2024

Project leader: Paula Ossowicz-Rupniewska, PhD

Amount of granted funds: PLN 1 500 000.00 PLN

Grant as part of the NCBiR LIDER XI competition

Project no: LIDER / 53/0225 / L-11/19 / NCBR / 2020


Pulaski Str. 10, 70-322 Szczecin, POLAND

(+48) 91 449 48 01

Thanks for submitting!

Robotic Lab Assistant
bottom of page